Tandem Diabetes Care

Tandem Diabetes Care will pay Roche $36 million over five years to resolve patent infringement claims related to Tandem's t:slim X2 insulin pump.

Medtronic has submitted 510(k) applications to the FDA for its MiniMed 780G pump as an alternate controller enabled device and its SmartGuard algorithm as an interoperable automated glycemic controller.

Dexcom's new 15-day continuous glucose monitor demonstrates 8% mean absolute relative difference, positioning it as the most accurate CGM on the market while awaiting FDA clearance expected in the second half of 2023.

Tandem Diabetes Care has received FDA clearance for its Control-IQ+ algorithm, expanding automated insulin delivery system access to all Type 2 diabetes patients using insulin pumps.